Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539744 · ClinicalTrials.gov registry record · Phase 3
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
A Phase 3 study of Multiple Myeloma, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 265
- Enrollment target
- 20
- Study locations
NCT03539744 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 265 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT03539744, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 265 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Dexamethasone
- DRUG Pomalidomide
Study Locations (20)
California
- VA Central California Health Care System /ID# 200047 - Fresno
- University of California, Los Angeles /ID# 171524 - Los Angeles
Florida
- Mayo Clinic /ID# 200075 - Jacksonville
- Cleveland Clinic Florida /ID# 208884 - Weston
Michigan
- Barbara Ann Karmanos Cancer In /ID# 201377 - Detroit
- Duplicate_Henry Ford Hospital /ID# 171531 - Detroit
Ohio
- Fairview Hospital - Moll Pavilion /ID# 208919 - Cleveland
- Cleveland Clinic Main Campus /ID# 202247 - Cleveland
Arizona
- Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 - Tucson
Colorado
- Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 222904 - Aurora
Kentucky
- Duplicate_Norton Cancer Institute /ID# 200834 - Louisville
Maryland
- University of Maryland, Baltimore /ID# 217422 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2027-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539744
The ClinicalTrials.gov registry entry for NCT03539744 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (51% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT03539744 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03539744 about?
NCT03539744 is a clinical study titled "A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.". A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
What is the current status of trial NCT03539744?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 265 participants. The study started on 2018-10-22. Estimated completion is 2027-11.
What conditions does trial NCT03539744 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03539744?
The interventions under investigation include: Venetoclax (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT03539744?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03539744 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.